Shane Health, CEO of the functional mushroom company MUD\WTR, made an open statement allowing employees to microdose at work.
He estimates that about 20% of employees microdose on the job, including himself and senior designer Ryan Rosenthal.
“It’s really good as a designer because we’re really trying to think about the psychology of who’s visiting our platform, and so you can really tap into that and become more empathetic,” Rosenthal explains.
Pro tip: if you accidentally take a bit too much, “it’s nothing that a quick walk and a coconut water can’t fix.”
MUD\WTR had no current job openings in case you were about to check 😉
— CYB003 is the first psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder —
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announce the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its Phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”).
“Following the successful completion of our IND-enabling work just last month, we are very excited to have reached this major milestone toward advancing CYB003 into clinical development so quickly. Based on preclinical studies, our proprietary psilocybin analog has the potential to offer numerous advantages over classic psilocybin with the potential to ultimately provide better outcomes for people suffering with MDD,” said Doug Drysdale, Chief Executive Officer of Cybin. “This FDA submission is the next major step in the advancement of CYB003, and we continue to work tirelessly to bring this innovative therapeutic option to people as quickly as possible. We look forward to continuing to work with the FDA to initiate the Phase 1/2a trial in mid-2022.”
About the CYB003 Phase 1/2a Trial The Phase 1/2a trial is a randomized, double blind, placebo-controlled study evaluating people with moderate to severe MDD. Subjects will receive two administrations (placebo/active and active/active) and a response/remission will be assessed at Week 3 (after single dose) and at Week 6 (after receiving a second dose). Using the Montgomery-Asberg Depression Rating Scale, the trial will assess rapid onset of antidepressant effect on the day of dosing. The study will also evaluate the benefit of more than one administration and will provide pharmacokinetic (“PK”) and safety data. The trial design will allow for people to continue their treatment with selective serotonin reuptake inhibitors (“SSRIs”). An optional open-label follow-up study (up to 12 weeks) will allow an assessment of durability of treatment effects.
“Through this Phase 1/2a trial, we are primarily looking to demonstrate the improved PK and safety profile of CYB003, as well as efficacy. We have designed the trial to allow people to continue to take their antidepressant medication, which will also allow us to assess the effect of CYB003 on people who are treated with an SSRI. At this time, we expect to have a PK and safety data readout by the end of 2022,” concluded Drysdale.
The Company has engaged Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Phase 1/2a clinical trial of CYB003.
The detailed Phase 1/2a study protocol is available at clinicaltrials.gov under the Identifier number: NCT05385783.
About CYB003 CYB003 is derived from psilocybin, which is part of a family of molecules called indolamines that include more common neurotransmitters, such as serotonin. Psilocybin is dephosphorylated to form its metabolite, psilocin, which can cross the blood-brain-barrier. Given its structural similarity to serotonin, psilocin can easily activate the serotonin 5-HT2A receptor. CYB003 is a deuterated psilocybin analog designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability. CYB003 has the potential to effectively treat MDD and alcohol use disorder.
About Cybin Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Cautionary Notes and Forward-Looking Statements Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the Company’s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens to potentially treat psychiatric disorders.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company’s management’s discussion and analysis for the period ended December 31, 2021 and the Company’s listing statement dated November 9, 2020, which are available under the Company’s profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.
Neither the NEO Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Investor & Media: Leah Gibson Vice President, Investor Relations & Strategic Communications Cybin Inc. irteam@cybin.com – or – media@cybin.comSource: Cybin
Shrooms are known to cause nausea, so you wouldn’t expect them to help with digestive issues.
However, the Toronto-based startup Dyscovry Science Ltd. is developing a synthetic psilocybin formulation to target irritable bowel syndrome (IBS). Psilocybin’s anti-inflammatory effect may help with the disorder.
The preliminary research must be promising because Silo Wellness (SILO) just entered into an agreement to acquire 100% of Dyscovry Science.
In partnership with Red Light Holland (TRIP), multi-platinum rapper Wiz Khalifa is starting a psychedelic and functional mushroom brand called MISTERCAP.
Red Light Holland hopes to leverage Khalifa’s huge following and entrepreneurial success in the cannabis industry to help end the stigma surrounding psilocybin.
The brand will sell:
Recreational psilocybin truffles in the Netherlands (potentially expanding to other markets if legalized)
Mushroom growing kits in the US, Canada, and Europe (launching by the end of this year)
Red Light Holland also announced that it’s starting a new program to provide advice and funding to business owners who are looking to enter Oregon’s legal psilocybin therapy market.
Halucenex to receive recently harvested first batch of psilocybe cubensis
VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Halucenex Life Sciences Inc. (“Halucenex”), a wholly owned subsidiary of Creso Pharma of Australia (ASX: CPH). Halucenex is based in Windsor, Nova Scotia and is a life sciences company focused on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine.
Additionally, Optimi wishes to confirm that the supply agreement pertains to the entirety of the Company’s recently harvested first batch of psilocybe cubensis mushrooms at its Princeton, British Columbia facility. The mushrooms will be supplied to Halucenex in the form of whole, dried mushroom fruiting bodies.
“This first supply agreement, coming so soon after our first complete cultivation cycle, is a powerful affirmation of our decision to pursue the development of natural, GMP psilocybin,” said Bill Ciprick, CEO of Optimi. “From this initial proof-of-concept batch, our cultivation team will continue to scale our operations to meet the demands of the sector, domestically and internationally with licensed entities and for individual patients within Canada according to the terms of the Special Access Program.”
Halucenex CEO, Bill Fleming, says the agreement with Optimi is one both companies will benefit from.
“We’re very excited to be moving forward on this supply agreement with the team at Optimi Health,” said Fleming. “Among our top priorities in the development of a psychedelic-assisted psychotherapeutic model for conditions such as anxiety and post-traumatic stress disorder has been to secure a safe, consistent supply of GMP psilocybin.”
Authorized parties interested in purchasing Optimi psilocybin and functional mushroom products should send an email to sales@optimihealth.ca where a member of the sales team will respond within 24 hours.
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
Optimi Health Inc. is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets. Built with the purpose to produce scalable, natural mushroom formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe, natural GMP grade psilocybin across the world. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.
To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of psilocybin and psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of psilocybin and psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
Optimi was recently granted an amendment to its Dealer’s Licence by Health Canada, allowing the Company to possess a quota of up to 5000kg of dried psilocybin mushrooms – the equivalent of 10kg of psilocybin – and 100g of psilocin.
ABOUT HALUCENEX
Halucenex operates a 6000 sq ft medical facility in Windsor, Nova Scotia with six treatment rooms and a secure laboratory dedicated to performing psychedelic-assisted psychotherapy and clinical research. Halucenex intends to maintain control over all aspects of the product development process – mycological research, extraction technology, and synthetic formulation as well as drug delivery technologies, psychedelic-assisted psychotherapy and regulatory affairs.
Clinically, Halucenex is focused on researching psilocybin, psilocybin-derivatives, and other psychedelic medicine for the purposes of treating clients suffering from PTSD and anxiety using its comprehensive psilocybin-assisted psychotherapy treatment model. Halucenex is committed to advancing the science around the use of psilocybin in psychedelic-assisted psychotherapy by:
For more information or to request an interview, please contact:
Michael Kydd Media & Stakeholder Relations Advisor Email: michael@kyddergroup.com Phone: +1 (902) 880 6121
(Quw’utsun’/ Duncan, B.C.) – Vancouver Island craft cannabis farmers, processors and psilocybin producers are invited to participate in a special one-day roundtable meeting in Duncan on Thursday, June 16 with patients, elected officials, community, business and Indigenous leaders.
The goals of the community roundtable are:
to identify economic and social development opportunities common to Vancouver Island’s internationally recognized craft cannabis and psilocybin producers; and
to discuss partnerships and pathways to achieve these opportunities in the public interest.
Among other things, discussion topics will focus on:
collaborations with Indigenous, provincial and federal governments;
domestic and international tourism;
expanded medical access and treatment options for people suffering from chronic disease and addiction;
Roundtable meeting space is limited. Please RSVP to info@bccraftfarmerscoop.com. A full event agenda and special guests will be published over the coming days.
Based on Vancouver Island, TheraPsil is a non-profit coalition of healthcare professionals, patients, and advocates dedicated to obtaining access to safe, effective, and legal psilocybin-assisted psychotherapy for Canadians. Over the past two years, TheraPsil has successfully advocated securing more than 80 exemptions from the federal Minister of Health for Canadians to legally possess psilocybin (aka magic mushrooms) for medical purposes.
The BC Craft Farmers Co-op (BCCFC) was founded in 2020 to provide B.C.’s small cannabis producers and processors with a safe, accessible, and sustainable alternative to the illicit market and ensure BC’s international reputation as an international cannabis leader and innovator is maintained. BCCFC members and supporters include BC craft farmers, processors, nurseries, testing labs, independent retailers, consumers, and sector vendors.
Company to focus on supply agreements and working directly with Canadians and physicians
VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce an historical milestone in the Company’s road to commercialization with the successful completion of its first batch of psilocybin cubensis and functional mushrooms.
With the vast availability of Optimi’s newly acquired genetics and recent amendment to its Health Canada’s Dealer’s Licence, Optimi is positioned to lead the industry in the scalable cultivation of mushrooms and is ready to deliver on the Company’s promise of building a future where natural psychedelic alternatives aid a wide variety of mental health conditions.
“It has been an amazing two-year journey getting to where we are today,” said Bill Ciprick, Optimi CEO. “Having now cultivated our first grow of psilocybin and functional mushrooms to a GMP standard, we are excited to be at full operational capacity and will proceed with domestic and international supply agreements with drug development companies and patients through the Special Access Program (SAP).”
Parties interested in purchasing Optimi psilocybin and functional products should send an email to sales@optimihealth.ca where a member of the sales team will respond within 24 hours.
Ciprick credits the Company’s success on the hard work of Optimi Chief Science Officer, Justin Kirkland, and new Head of Cultivation, Todd Henderson.
Henderson, an Alberta born Metis proud of his Cree heritage, started cultivating mushrooms in 1991 at the age of 15 after spending his summer on the Grouard Reserve near High Prairie Alberta. It was there that his father’s cousin Edgar instructed him in the medicine of mushrooms and helped him find clarity and wisdom from the Great Spirit, Kitchi Manitou.
“That summer, I was sent home with spore prints as a way to honour my ancestors and pass my knowledge on to a new generation – it is the way of our people,” said Henderson. “We are living in extraordinary times, and I believe the lessons of my father and Edgar serve a bigger purpose in helping all people heal from the mental health crisis we see today. I am grateful that Optimi has given me this opportunity to share my knowledge. I am Cree! Neya Nehiyaw.” concluded Henderson.
Henderson supervised the eight-week cultivation process at the Company’s 20,000 square foot, technologically scaled EU-GMP grow facilities in Princeton, British Columbia, and will be giving public tours of his work at Optimi’s Grand Opening celebration on May 27th.
For those interested in attending the in-person event or via livestream should contact event organizer, Michael Kydd, at info@kyddergroup.com.
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
Optimi Health is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets. Built with the purpose to produce scalable, natural mushroom formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe, natural GMP grade psilocybin across the world. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.
To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:
This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.
Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.
Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Optimi Health Head of Cultivation and Master Grower, Todd Henderson
Ceruvia Lifesciences submitted an application to study psilocybin as a treatment for obsessive-compulsive disorder (OCD) in a Phase 2 trial.
Preliminary findings suggest that psilocybin causes a “rapid and robust improvement in OCD symptoms with a sustained effect,” according to the press release.
The trial, which will be led by Yale researchers later this year if approval is granted, will determine if these findings hold true when psilocybin is compared to an active placebo.
CEO Todd Shapiro will interview Russell Peters later today, May 24th, at 8 PM CET / 2PM ET in front of an invite only audience about Russell’s candid journey with Red Light’s Therapist Jeff Hamburg
This unique candid Red Light Event will be live streamed on Russell Peters’ Twitter account (@TheRealRussellP – 3.9m) plus Todd Shapiro’s and Red Light Holland’s social media accounts May 24th 2 PM ET
The Live event will be held in a secret central location in a popular Amsterdam hotel with an exclusive VIP party after the Q&A
Toronto, Ontario–(Newsfile Corp. – May 24, 2022) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce Russell Peters, the company’s Chief Creative Officer, currently in Amsterdam, has completed his first psychedelic journey.
Russell Peters and therapist Jeff Hamburg before the Psilocybin Journey
Russell carefully used Red Light Holland’s premium psilocybin truffles and was guided by Red Light Holland’s therapist and expert psychedelic guide Jeff Hamburg. Peters will have a special Q&A session in front of a live audience which will be live-streamed on Russell Peters’ Twitter account (@TheRealRussellP – 3.9m followers) plus Todd Shapiro’s and Red Light’s Holland’s social media accounts on May 24th (later today) now that Russell has completed his psychedelic journey.
The Q&A will be hosted by CEO Todd Shapiro and the event will air live on May 24th at 2 PM ET. The Q&A will be followed by an exclusive VIP party.
“We did it! I’m proud, I’m feeling great and I’m excited to share my journey to the world, later today, with my buddy Todd Shapiro,” said Red Light CCO Russell Peters.
“Russell joked with me that this was supposed to be his down time on his global comedy tour! I mean here’s a guy who just played in Dubai and most recently at Wembley Stadium in London – yet he made invaluable time for all of us at Red Light Holland,” said CEO and Director Todd Shapiro. “Please tune in to Russell Peters’ Twitter handle – @TheRealRussellP (3.9m followers) or my (@IAmToddyTickles) social media handles (approx 60k followers) or all Red Light Holland social media handles at 2pm ET for the Q&A! And if you miss the livestream don’t worry – like a podcast – this will continue to be online for as long as you want to watch or listen to it! Tell your friends and family as we are proud to have a bigger and broader conversation around ending the stigma around psychedelics with the continued hope of helping create positive change.”
About Red Light Holland
Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release
Forward-Looking Statements
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or their respective subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Examples of such information include statements with respect to: the ability for Russell Peters and Todd Shapiro to host the live stream on May 24th in the Netherlands, the intimate live event featuring Russell Peters hosted by Todd Shapiro and the live-streaming of the event; the commencement and projected date regarding the Company’s ability to ensure the live event will happen on the Company’s social media accounts or on Russell Peters’ social media Twitter account (3.9m followers) or on Todd Shapiro’s social media accounts (approx 60k followers,) the venue for the event; statements about the future of the live session with Russell Peters and Todd Shapiro; that the company will have the live q&a at a secret, popular Amsterdam hotel.
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, expectations regarding future growth and expansion of the operations of the business; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; risks related to infectious diseases, including the impacts of the COVID-19 pandemic; legal and regulatory risks inherent in the psychedelics industry, including the global regulatory landscape and enforcement related to psychedelics; political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the psychedelics industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com, including the Company’s annual information form for the year ended March 31, 2020.
Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws
The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
Vancouver, British Columbia–(Newsfile Corp. – May 24, 2022) – Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the “Company”), a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products announces that its strategic partners Symeres are licensed to produce large quantities of controlled compounds required by Nirvana.
The company is excited to announce that strategic partner Symeres has confirmed with Nirvana Life Sciences, its ability to produce up to 1000g batches of pharmaceutical Psilocybin and Psilocin. These batches can then be utilized for sale to qualified investigators for use in research and development of such compounds as well as pre-clinical and clinical trials. Nirvana believes there will be significant demand for psychedelic compounds, as an ever growing number of clinical trials and research is taking place within the psychedelic sector. This will give Nirvana Life Sciences the ability to provide a bridge to a consistent source of pharmaceutical grade, psychedelic compounds to significantly evolve and further the global psychedelic sector.
Mr. Michael McCune, Vice President Operations, stated “This is very good news for Nirvana as it gives us the ability to facilitate the supply of pharmaceutical grade psychedelic compounds before being granted a license by Health Canada. Being well into our licensing process with Health Canada, this gives us the ability to procure and form supply chain partnerships early on.”
About Nirvana Life Sciences Inc.
Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that can provide healthier outcomes for patients who live with chronic pain and/or have battled with addiction. Nirvana believes that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction. Nirvana’s team, consisting of leading researchers from around the globe, will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually.
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company’s actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
